Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAR-210 (Erdafitinib Intravesical Delivery System) in Japanese Participants With Bladder Cancer and FGFR Alterations
jRCT2041220101Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erdafitinib in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer, sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with dose-limiting toxicity (DLT). Started Oct 2023; status: completed.
02
Drugs
erdafitinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on jRCT2041220101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220101.